GME751 is a proposed biosimilar to pembrolizumab. It is being studied to see if it is safe for patients who have already been receiving pembrolizumab in previous studies. Pembrolizumab is a type of medication known as an immune checkpoint inhibitor, which helps the body’s immune system fight cancer by blocking a specific protein that prevents immune cells from attacking cancer cells. This trial aims to ensure that GME751 can continue to provide similar benefits and safety as pembrolizumab for patients who need ongoing treatment.

Melanoma – Melanoma is a type of skin cancer that begins in the melanocytes, which are the cells responsible for producing the pigment melanin. It often appears as a new mole or a change in an existing mole, with irregular borders and multiple colors. Melanoma can grow quickly and has the potential to spread to other parts of the body if not detected early. It is more common in areas of the skin that have been exposed to the sun, but it can also occur in areas not typically exposed. The progression of melanoma can vary, with some cases remaining localized while others may metastasize. Early detection and monitoring of skin changes are crucial in managing this disease.

Non-small-cell lung cancer – Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for a majority of cases. It typically starts in the epithelial cells lining the lungs and can grow slowly or rapidly, depending on the subtype. NSCLC is often diagnosed at an advanced stage because early symptoms can be mild or mistaken for other conditions. As the cancer progresses, it can invade nearby tissues and spread to other parts of the body, such as the bones or brain. The disease is categorized into several subtypes, including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, each with distinct characteristics. Understanding the specific subtype is important for determining the course of the disease.